STAT Pharmalittle (June 30): US Lawmakers Investigating Whether Several Large Drugmakers Have Been Involved in Chinese Clinical Trial Sites That Helped Fuel Country's Military Capability: Parallel Track to the BIOSECURE Act and the Insilico-SK Biopharm $2.5B AI Neuroimmune Deal Anchoring BIO 2026 Last Week
STAT News' Pharmalittle column on Tuesday June 30, 2026 disclosed that US lawmakers are investigating whether several large pharmaceutical companies have been involved in clinical trials at Chinese sites that helped advance China's military capability. The investigation runs parallel to the BIOSECURE Act (passed 2024) restricting US biotech contracting with named Chinese CDMOs and gene-sequencing companies, and to the structural anxiety about Chinese scientific output that biotech executives flagged at BIO 2026 last week. The Insilico Medicine (Hong Kong-headquartered) + SK Biopharmaceuticals $2.5 billion AI-neuroimmune drug discovery pact announced June 22 at BIO 2026 opening sits inside this conversation, as do Chinese-API supply chains feeding US gray-market peptide vendors and the licensed-generic semaglutide flow from Indian and Chinese manufacturers post-March 2026 patent expiration. The lawmaker probe expands the regulatory aperture beyond the BIOSECURE Act's named-entity list toward broader scrutiny of US-China clinical-research cooperation. No specific drugmakers were publicly named in the Pharmalittle report.